Breaking News
UiPath Exceeds Expectations with Record Sales and Profitable Quarter
UiPath has exceeded expectations in Q4 of 2024, achieving record sales and marking its first profitable quarter since going public....
MicroStrategy Announces 500 Million Private Offering for Bitcoin Procurement
MicroStrategy has unveiled a new proposal for a private offering of $500 million in convertible senior notes due in 2031....
Title Ocean Power Technologies Reports Revenue Growth in Third Quarter 2024
On March 13, 2024, Ocean Power Technologies revealed a third quarter EPS of $(0.11), consistent with the previous year. ====================...
FTC Solar Reports Mixed Q4 Financial Results with Focus on Future Growth
FTC Solar announced its Q4 financial results on March 13, 2024, revealing a mixed performance. The company reported a quarterly...
Quoin Pharmaceuticals Exceeds Q4 Earnings Expectations
Quoin Pharmaceuticals' Q4 Earnings Report Unveiled On March 13, 2024, Quoin Pharmaceuticals (NASDAQ: QNRX) disclosed its Q4 earnings, shedding light...
Spruce Biosciences Reports Improved Financial Performance and Strategic CostCutting Measures for FY23
Spruce Biosciences announced an EPS of $(1.24) for FY23, marking an improvement from $(1.96) compared to the previous year. Collaboration...
Vroom Inc Q4 Financial Results Impact Stock Performance and Future Outlook
Vroom Inc. released its Q4 financial results on March 13, 2024, impacting its stock performance significantly. Here is a breakdown...
Cue Health NASDAQ HLTH Q4 Earnings Report Key Highlights
Cue Health (NASDAQ: HLTH) released its Q4 earnings on March 13, 2024, revealing some key highlights: - Earnings: Cue Health...
Title Poseida Therapeutics Receives Orphan Drug Designation for PBCMAALLO1 Targeting Multiple Myeloma
On March 13, 2024, Poseida Therapeutics received Orphan Drug Designation from the FDA for their innovative treatment, P-BCMA-ALLO1, targeting Multiple...
Needham Analyst Reiterates Buy Rating and 28 Price Target for Liquidia Technologies
Needham analyst Serge Belanger has reiterated his Buy rating and $28 price target for Liquidia (NASDAQ:LQDA) on March 13, 2024....
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
